| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Physical Medicine & Rehabilitation (Dr. Foster) and Neurology (Drs. Erickson and Jabbari), Walter Reed Army Medical Center, Washington, DC; Department of Neurology (Drs. Foster, Erickson, and Jabbari), Uniformed Services University, Bethesda, MD; and the Neurology Service (Dr. Clapp), Veterans Administration Hospital, Huntington, WV.
Address correspondence and reprint requests to Dr. Bahman Jabbari, Department of Neurology, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814.
OBJECTIVES: To investigate the efficacy of botulinum toxin A in chronic low back pain and associated disabilities.
METHODS: Thirty-one consecutive patients with chronic low back pain who met the inclusion criteria were studied: 15 received 200 units of botulinum toxin type A, 40 units/site at five lumbar paravertebral levels on the side of maximum discomfort, and 16 received normal saline. Each patient’s baseline level of pain and degree of disability was documented using the visual analogue scale (VAS) and the Oswestry Low Back Pain Questionnaire (OLBPQ). The authors reevaluated the patients at 3 and 8 weeks (visual analogue scale) and at 8 weeks (OLBPQ).
RESULTS: At 3 weeks, 11 of 15 patients who received botulinum toxin (73.3%) had >50% pain relief vs four of 16 (25%) in the saline group (p = 0.012). At 8 weeks, nine of 15 (60%) in the botulinum toxin group and two of 16 (12.5%) in the saline group had relief (p = 0.009). Repeat OLBPQ at 8 weeks showed improvement in 10 of 15 (66.7%) in the botulinum toxin group vs three of 16 (18.8%) in the saline group (p = 0.011). No patient experienced side effects.
CONCLUSION: Paravertebral administration of botulinum toxin A in patients with chronic low back pain relieved pain and improved function at 3 and 8 weeks after treatment.
This article has been cited by other articles:
|
|
 |
|
  M. Naumann, Y. So, C. E. Argoff, M. K. Childers, D. D. Dykstra, G. S. Gronseth, B. Jabbari, H. C. Kaufmann, B. Schurch, S. D. Silberstein, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, May 6, 2008; 70(19): 1707 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Richards, E . Qerama, A . Fuglsang-Frederiksen, H . Kasch, F .W. Bach, and T .S. Jensen A double-blind, controlled study of botulinum toxin A in chronic myofascial pain Neurology, March 20, 2007; 68(12): 963 - 964. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Abbott, S. K. Jarvis, S. D. Lyons, A. Thomson, and T. G. Vancaille Botulinum toxin type a for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet. Gynecol., October 1, 2006; 108(4): 915 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Qerama, A. Fuglsang-Frederiksen, H. Kasch, F. W. Bach, and T. S. Jensen A double-blind, controlled study of botulinum toxin A in chronic myofascial pain. Neurology, July 25, 2006; 67(2): 241 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Park, Y. Lee, J. Lee, C. Park, and D. E. Moon The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain: [Les effets de la toxine botulique A sur l'allodynie mecanique et l'allodynie au froid chez un modele de douleur neuropathique chez le rat]. Can J Anesth, May 1, 2006; 53(5): 470 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ghazizadeh and M. Nikzad Botulinum Toxin in the Treatment of Refractory Vaginismus Obstet. Gynecol., November 1, 2004; 104(5): 922 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Jankovic Botulinum toxin in clinical practice J. Neurol. Neurosurg. Psychiatry, July 1, 2004; 75(7): 951 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Voller, T. Sycha, B. Gustorff, L. Schmetterer, S. Lehr, H. G. Eichler, E. Auff, and P. Schnider A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A Neurology, October 14, 2003; 61(7): 940 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Delgado Botulinum Neurotoxin Type A J. Am. Acad. Ortho. Surg., September 1, 2003; 11(5): 291 - 294. [Full Text] [PDF]
|
|
|
|
 |
|
 R. F Robinson and M. C Nahata Management of Botulism Ann. Pharmacother., January 1, 2003; 37(1): 127 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Botulinum Toxin Injections for Chronic Low Back Pain Journal Watch (General), June 1, 2001; 2001(601): 1 - 1. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
